These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
391 related articles for article (PubMed ID: 36184662)
1. Statins, Type 2 Diabetes, and Body Mass Index: A Univariable and Multivariable Mendelian Randomization Study. Yang G; Schooling CM J Clin Endocrinol Metab; 2023 Jan; 108(2):385-396. PubMed ID: 36184662 [TBL] [Abstract][Full Text] [Related]
2. Investigating the effects of statins on ischemic heart disease allowing for effects on body mass index: a Mendelian randomization study. Li S; Schooling CM Sci Rep; 2022 Mar; 12(1):3478. PubMed ID: 35241713 [TBL] [Abstract][Full Text] [Related]
3. A phenome-wide association study of genetically mimicked statins. Li S; Schooling CM BMC Med; 2021 Jun; 19(1):151. PubMed ID: 34187478 [TBL] [Abstract][Full Text] [Related]
4. Lipid traits and type 2 diabetes risk in African ancestry individuals: A Mendelian Randomization study. Soremekun O; Karhunen V; He Y; Rajasundaram S; Liu B; Gkatzionis A; Soremekun C; Udosen B; Musa H; Silva S; Kintu C; Mayanja R; Nakabuye M; Machipisa T; Mason A; Vujkovic M; Zuber V; Soliman M; Mugisha J; Nash O; Kaleebu P; Nyirenda M; Chikowore T; Nitsch D; Burgess S; Gill D; Fatumo S EBioMedicine; 2022 Apr; 78():103953. PubMed ID: 35325778 [TBL] [Abstract][Full Text] [Related]
5. Associations between Genetically Proxied Inhibition of Lipid-Lowering Drug Targets and Serum Micronutrients among Individuals of European Descent: A Mendelian Randomization Study. He JY; Zhang X; Wang K; Lv WQ J Nutr; 2022 May; 152(5):1283-1290. PubMed ID: 35349717 [TBL] [Abstract][Full Text] [Related]
6. Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer. Yarmolinsky J; Bull CJ; Vincent EE; Robinson J; Walther A; Smith GD; Lewis SJ; Relton CL; Martin RM JAMA; 2020 Feb; 323(7):646-655. PubMed ID: 32068819 [TBL] [Abstract][Full Text] [Related]
7. Investigating sex-specific associations of lipid traits with type 2 diabetes, glycemic traits and sex hormones using Mendelian randomization. Yang G; Schooling CM Cardiovasc Diabetol; 2023 Jan; 22(1):3. PubMed ID: 36624450 [TBL] [Abstract][Full Text] [Related]
8. Association of lipid-lowering drug targets with risk of cutaneous melanoma: a mendelian randomization study. Miao L; Miao T; Zhang Y; Hao J BMC Cancer; 2024 May; 24(1):602. PubMed ID: 38760735 [TBL] [Abstract][Full Text] [Related]
9. Risk of Neuropsychiatric Adverse Effects of Lipid-Lowering Drugs: A Mendelian Randomization Study. Alghamdi J; Matou-Nasri S; Alghamdi F; Alghamdi S; Alfadhel M; Padmanabhan S Int J Neuropsychopharmacol; 2018 Dec; 21(12):1067-1075. PubMed ID: 29986042 [TBL] [Abstract][Full Text] [Related]
10. Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: A Mendelian randomization study. Gormley M; Yarmolinsky J; Dudding T; Burrows K; Martin RM; Thomas S; Tyrrell J; Brennan P; Pring M; Boccia S; Olshan AF; Diergaarde B; Hung RJ; Liu G; Legge D; Tajara EH; Severino P; Lacko M; Ness AR; Davey Smith G; Vincent EE; Richmond RC PLoS Genet; 2021 Apr; 17(4):e1009525. PubMed ID: 33886544 [TBL] [Abstract][Full Text] [Related]
11. Genetically proxied therapeutic inhibition of lipid-lowering drug targets and risk of rheumatoid arthritis disease: a Mendelian randomization study. Qiao L; Lv S; Meng K; Yang J Clin Rheumatol; 2024 Mar; 43(3):939-947. PubMed ID: 38198113 [TBL] [Abstract][Full Text] [Related]
12. PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. Schmidt AF; Swerdlow DI; Holmes MV; Patel RS; Fairhurst-Hunter Z; Lyall DM; Hartwig FP; Horta BL; Hyppönen E; Power C; Moldovan M; van Iperen E; Hovingh GK; Demuth I; Norman K; Steinhagen-Thiessen E; Demuth J; Bertram L; Liu T; Coassin S; Willeit J; Kiechl S; Willeit K; Mason D; Wright J; Morris R; Wanamethee G; Whincup P; Ben-Shlomo Y; McLachlan S; Price JF; Kivimaki M; Welch C; Sanchez-Galvez A; Marques-Vidal P; Nicolaides A; Panayiotou AG; Onland-Moret NC; van der Schouw YT; Matullo G; Fiorito G; Guarrera S; Sacerdote C; Wareham NJ; Langenberg C; Scott R; Luan J; Bobak M; Malyutina S; Pająk A; Kubinova R; Tamosiunas A; Pikhart H; Husemoen LL; Grarup N; Pedersen O; Hansen T; Linneberg A; Simonsen KS; Cooper J; Humphries SE; Brilliant M; Kitchner T; Hakonarson H; Carrell DS; McCarty CA; Kirchner HL; Larson EB; Crosslin DR; de Andrade M; Roden DM; Denny JC; Carty C; Hancock S; Attia J; Holliday E; O'Donnell M; Yusuf S; Chong M; Pare G; van der Harst P; Said MA; Eppinga RN; Verweij N; Snieder H; ; Christen T; Mook-Kanamori DO; Gustafsson S; Lind L; Ingelsson E; Pazoki R; Franco O; Hofman A; Uitterlinden A; Dehghan A; Teumer A; Baumeister S; Dörr M; Lerch MM; Völker U; Völzke H; Ward J; Pell JP; Smith DJ; Meade T; Maitland-van der Zee AH; Baranova EV; Young R; Ford I; Campbell A; Padmanabhan S; Bots ML; Grobbee DE; Froguel P; Thuillier D; Balkau B; Bonnefond A; Cariou B; Smart M; Bao Y; Kumari M; Mahajan A; Ridker PM; Chasman DI; Reiner AP; Lange LA; Ritchie MD; Asselbergs FW; Casas JP; Keating BJ; Preiss D; Hingorani AD; ; Sattar N Lancet Diabetes Endocrinol; 2017 Feb; 5(2):97-105. PubMed ID: 27908689 [TBL] [Abstract][Full Text] [Related]
13. Drug Target Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Atrial Fibrillation. Li F; Mei Y; Wu Q; Wu X Cardiology; 2024; 149(5):495-501. PubMed ID: 38531334 [TBL] [Abstract][Full Text] [Related]
14. Investigating genetically mimicked effects of statins via HMGCR inhibition on immune-related diseases in men and women using Mendelian randomization. Yang G; Schooling CM Sci Rep; 2021 Dec; 11(1):23416. PubMed ID: 34862478 [TBL] [Abstract][Full Text] [Related]
15. Effects of ACLY Inhibition on Body Weight Distribution: A Drug Target Mendelian Randomization Study. Gill D; Dib MJ; Gill R; Bornstein SR; Burgess S; Birkenfeld AL Genes (Basel); 2024 Aug; 15(8):. PubMed ID: 39202419 [No Abstract] [Full Text] [Related]
16. Effects of genetically proxied statins on diabetic nephropathy and retinopathy: a Mendelian randomization study. Zhao R; Wang W; Zhang W; Lu J; Liu Y; Guo J; Yang L; Zhang Z; He C; Gu X; Wang B Sci Rep; 2024 Jul; 14(1):16885. PubMed ID: 39043809 [TBL] [Abstract][Full Text] [Related]
17. Association of Lipid-Lowering Drugs With Risk of Psoriasis: A Mendelian Randomization Study. Zhao SS; Yiu ZZN; Barton A; Bowes J JAMA Dermatol; 2023 Mar; 159(3):275-280. PubMed ID: 36696131 [TBL] [Abstract][Full Text] [Related]
18. Causal Association of Type 2 Diabetes Mellitus and Glycemic Traits With Cardiovascular Diseases and Lipid Traits: A Mendelian Randomization Study. Huang M; Laina-Nicaise LD; Zha L; Tang T; Cheng X Front Endocrinol (Lausanne); 2022; 13():840579. PubMed ID: 35528012 [TBL] [Abstract][Full Text] [Related]
19. Genetically mimicked effects of ASGR1 inhibitors on all-cause mortality and health outcomes: a drug-target Mendelian randomization study and a phenome-wide association study. Yang G; Schooling CM BMC Med; 2023 Jul; 21(1):235. PubMed ID: 37400795 [TBL] [Abstract][Full Text] [Related]
20. Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer. Sun L; Ding H; Jia Y; Shi M; Guo D; Yang P; Wang Y; Liu F; Zhang Y; Zhu Z Breast Cancer Res; 2022 Feb; 24(1):12. PubMed ID: 35151363 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]